REGN News and Press, Regeneron Pharmaceuticals Inc.

2026-02-28 08:10:00 ET Introduction: Since Nov. 2025, the market has been mostly trading in a tight range between S&P 500 ( SPX ) levels 6600 and 6950. However, the S&P500 did cross the SPX7000 level briefly in January, but it has not done so in any meaningful way. There...

2026-02-27 10:49:43 ET More on Sanofi, Regeneron Pharmaceuticals Why Dupixent Keeps Regeneron A Top Big Pharma Pick Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued Regeneron: Expect Double-Digit Growth In 2026 Regeneron, Sanofi ...

2026-02-27 08:00:00 ET Shares of Regeneron Pharmaceuticals ( REGN ), my favorite on the monoclonal antibodies market, have risen 11.5% since the article "Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?" .... Read the full article on Seeking Alpha ...

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and r...

2026-02-27 02:54:16 ET Shares of antisense therapy concern Ionis Pharmaceuticals, Inc. ( IONS ) have rallied strongly since its familial chylomicronemia syndrome med Tryngolza (olezarsen) bore strong data treating severe hypertriglyceridemia. Announced in September 2025, the res...

Key Takeaways: Regeneron will extend its title sponsorship of the Regeneron Science Talent Search (STS) for a second decade, continuing its partnership with Society for Science to support the United States’ oldest and most prestigious science and mathematics competition for high school...

2026-02-24 19:36:00 ET Healthcare stocks have underperformed broader equities in recent years. But plenty of companies in the sector still look like good long-term bets. Take Regeneron Pharmaceuticals (NASDAQ: REGN) , a biotech leader. Although it's faced its share of headwinds ...

2026-02-24 10:32:21 ET More on Regeneron Pharmaceuticals Regeneron: Expect Double-Digit Growth In 2026 Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript Regeneron Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation Regen...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by...

2026-02-23 22:35:52 ET Company Background Electromed ( ELMD ) is a small medical device company based in Minnesota. It was founded in 1992 by Robert D. Hansen and Craig N. Hansen, and it IPO’d in 2010 at $4 a share. Shareholders did pretty poorly in the first 9 years ...